Is Editas Medicine Inc (EDIT) a Stock to Watch After Gaining 6.65% This Week?

The market has been high on Editas Medicine Inc (EDIT) stock recently. EDIT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Editas Medicine Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EDIT!

See Full EDIT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With EDIT Stock Today?

Editas Medicine Inc (EDIT) stock is trading at $10.43 as of 11:35 AM on Monday, Nov 27, a drop of -$0.15, or -1.42% from the previous closing price of $10.58. The stock has traded between $10.22 and $10.80 so far today. Volume today is low. So far 504,508 shares have traded compared to average volume of 1,775,367 shares. To see InvestorsObserver's Sentiment Score for Editas Medicine Inc click here.

More About Editas Medicine Inc

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Click Here to get the full Stock Report for Editas Medicine Inc stock.